NASDAQ:INBX Inhibrx Biosciences (INBX) Stock Price, News & Analysis $25.28 +1.12 (+4.63%) As of 10:48 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Inhibrx Biosciences Stock (NASDAQ:INBX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Inhibrx Biosciences alerts:Sign Up Key Stats Today's Range$24.00▼$25.4150-Day Range$14.27▼$24.5752-Week Range$10.81▼$25.41Volume13,389 shsAverage Volume105,031 shsMarket Capitalization$366.03 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingHold Company Overview Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California. Read More Inhibrx Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks38th Percentile Overall ScoreINBX MarketRank™: Inhibrx Biosciences scored higher than 38% of companies evaluated by MarketBeat, and ranked 704th out of 937 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Inhibrx Biosciences.Read more about Inhibrx Biosciences' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Inhibrx Biosciences are expected to decrease in the coming year, from $104.88 to ($12.08) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Inhibrx Biosciences is -2.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Inhibrx Biosciences is -2.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInhibrx Biosciences has a P/B Ratio of 5.11. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted6.86% of the float of Inhibrx Biosciences has been sold short.Short Interest Ratio / Days to CoverInhibrx Biosciences has a short interest ratio ("days to cover") of 6.5.Change versus previous monthShort interest in Inhibrx Biosciences has recently decreased by 24.67%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldInhibrx Biosciences does not currently pay a dividend.Dividend GrowthInhibrx Biosciences does not have a long track record of dividend growth. Sustainability and ESG4.6 / 5Environmental Score-1.21 Percentage of Shares Shorted6.86% of the float of Inhibrx Biosciences has been sold short.Short Interest Ratio / Days to CoverInhibrx Biosciences has a short interest ratio ("days to cover") of 6.5.Change versus previous monthShort interest in Inhibrx Biosciences has recently decreased by 24.67%, indicating that investor sentiment is improving significantly. News and Social Media2.6 / 5News Sentiment0.75 News SentimentInhibrx Biosciences has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Inhibrx Biosciences this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for INBX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Inhibrx Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders17.09% of the stock of Inhibrx Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions82.46% of the stock of Inhibrx Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Inhibrx Biosciences' insider trading history. Receive INBX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Inhibrx Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address INBX Stock News HeadlinesInhibrx Biosciences (NASDAQ:INBX) Upgraded by Wall Street Zen to "Hold" RatingAugust 19 at 2:47 AM | americanbankingnews.comInhibrx Biosciences, Inc.: Inhibrx Reports Second Quarter 2025 Financial ResultsAugust 14, 2025 | finanznachrichten.deNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’s Project MAFA,” and it could soon return America to a “new” gold standard. The Trump administration, Wall Street, and Silicon Valley are all pushing it forward. The President himself calls the plan “incredible.” Already, it’s helping small plays jump as high as 300%, 318%, 520%, and even 600%.August 22 at 2:00 AM | Brownstone Research (Ad)Inhibrx Reports Second Quarter 2025 Financial ResultsAugust 13, 2025 | prnewswire.comInhibrx Biosciences (INBX) Projected to Post Quarterly Earnings on TuesdayAugust 11, 2025 | americanbankingnews.comInhibrx Biosciences Advances HexAgon-HN Study for Head, Neck CancerJuly 29, 2025 | msn.comInhibrx Biosciences: Seeing Soon If The Momentum Is Just HypeJuly 18, 2025 | seekingalpha.comNoteworthy Tuesday Option Activity: INBX, ODP, AZO | NasdaqJuly 10, 2025 | nasdaq.comSee More Headlines INBX Stock Analysis - Frequently Asked Questions How have INBX shares performed this year? Inhibrx Biosciences' stock was trading at $15.40 at the beginning of the year. Since then, INBX shares have increased by 56.9% and is now trading at $24.16. How were Inhibrx Biosciences' earnings last quarter? Inhibrx Biosciences, Inc. (NASDAQ:INBX) issued its quarterly earnings results on Wednesday, August, 13th. The company reported ($1.85) earnings per share for the quarter, beating analysts' consensus estimates of ($2.92) by $1.07. The company had revenue of $1.30 million for the quarter. When did Inhibrx Biosciences IPO? Inhibrx Biosciences (INBX) raised $102 million in an initial public offering on Wednesday, August 19th 2020. The company issued 6,000,000 shares at a price of $16.00-$18.00 per share. Jefferies, Evercore ISI and Credit Suisse served as the underwriters for the IPO and LifeSci Capital was co-manager. Who are Inhibrx Biosciences' major shareholders? Top institutional shareholders of Inhibrx Biosciences include Perceptive Advisors LLC (6.75%), Sofinnova Investments Inc. (4.89%), Geode Capital Management LLC (1.56%) and Kennedy Capital Management LLC (1.22%). Insiders that own company stock include Brendan P Eckelman, Mark Lappe, Global Investors Lp Viking, Jon Faiz Kayyem and Kristiina Md Vuori. View institutional ownership trends. How do I buy shares of Inhibrx Biosciences? Shares of INBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Inhibrx Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Inhibrx Biosciences investors own include Meta Platforms (META), NVIDIA (NVDA), PayPal (PYPL), Shopify (SHOP), Zoom Communications (ZM), CrowdStrike (CRWD) and Moderna (MRNA). Company Calendar Last Earnings8/13/2025Today8/22/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:INBX CIK1739614 Webwww.inhibrx.com Phone858-795-4220FaxN/AEmployees166Year FoundedN/AProfitability EPS (Trailing Twelve Months)($10.58) Trailing P/E RatioN/A Forward P/E Ratio0.23 P/E GrowthN/ANet Income$1.69 billion Net MarginsN/A Pretax Margin-11,692.29% Return on Equity-137.83% Return on Assets-76.31% Debt Debt-to-Equity Ratio1.45 Current Ratio4.98 Quick Ratio4.98 Sales & Book Value Annual Sales$200 thousand Price / Sales1,749.18 Cash Flow$115.05 per share Price / Cash Flow0.21 Book Value$4.73 per share Price / Book5.11Miscellaneous Outstanding Shares14,480,000Free Float12,010,000Market Cap$349.84 million OptionableOptionable Beta0.24 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NASDAQ:INBX) was last updated on 8/22/2025 by MarketBeat.com Staff From Our Partners[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredUS attacks China, September 30?The White House just ordered more than 400 government agencies to prepare for the next phase of America’s econ...Stansberry Research | SponsoredOne tiny company just cracked Google’s $19B problemGoogle’s AI-powered search could cost $20 billion a year in electricity—nearly half its profits. But new resea...True Market Insiders | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibrx Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inhibrx Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.